Canadian Healthcare Technology Logo
  • Issues
    • Current Print Issue
    • Print Archive
  • Advertise
    • Publishing Schedule
    • Circulation
    • Unit Sizes and Rates
    • Mechanical Requirements
    • Electronic Advertising
    • White Papers
  • Subscribe
    • Print Edition
    • e-Messenger
    • White Papers
  • Events
  • Vendors
  • About Us

GE [April2023]

GE [April2023]

Enovacom – Nova Hospital

Enovacom - Nova Hospital

Research & Development

Researcher devises artificial copies of COVID-19 virus

October 28, 2020


Abdulla MahboobLONDON, Ont. – Fanshawe College’s Centre for Research and Innovation has developed a safe, rapid and inexpensive method to identify the effectiveness of potential COVID-19 drug treatments. Principal investigator Abdulla Mahboob (pictured), PhD in biotechnology with experience in the biochemistry of RNA viruses, has developed artificial copies of the SARS-COV-2 virus called ‘replicons’ that can be transferred into mammalian cells.

The replicons are non-infectious, containing all the non-structural genes of the virus, but missing the genes allowing the virus to assemble into an infectious agent. This enables testing of new COVID-19 drug therapies against the replicon outside of the more expensive biosafety level-2 laboratories.

Fanshawe’s replicon has also been developed with two problematic mutations in the current pandemic: one that is associated with higher mortality and another that is resistant against the current treatment remdesivir. Any pharmaceutical company would be able to use the lab-created replicons to rapidly screen a library of potential drug treatments for effectiveness against COVID-19.

“We are ready to work with a commercial partner who can actively participate in this venture to take our proof-of-concept success from our small college lab to large-scale application,” says Mahboob. “Our development, called the ‘Flexicon’, can make treatment testing much faster and more accessible to many labs around the world.”

Mahboob’s team is simultaneously working with the National Institutes of Health in the United States to validate a peptide-inhibitor treatment option for COVID-19.

“The faster we can effectively test the latest treatment options, the better our chances of potentially saving lives,” adds Mahboob.

For more information, contact Fanshawe’s Centre for Research and Innovation.

The initial laboratory proof-of-concept work was funded with support from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) through its contribution to the Niagara College-led Southern Ontario Network for Advanced Manufacturing Innovation (SONAMI).

PreviousNext

WP [900×150]

WP [900x150]

News and Trends

  • Breakthrough in data-sharing leads to better practices
  • Ottawa Heart Institute expands remote monitoring to surgical patients
  • Grandfather’s death inspires next generation of wound care technology
  • New Virtual Cockpit software gives technologists remote access to CT scanner
  • Apollo enterprise imaging solution moves to AWS cloud
More from the Print Edition

Subscribe

Subscribe

Free of charge to Canadian hospital managers and executives in nursing homes and home-care organizations. Learn More

Follow us on Social Media!

Follow us on Social Media!

Nihi Fall 2023

Nihi Fall 2023

Advertise with us

Advertise with us

Sectra SaaS

Sectra SaaS

Change Healthcare [2]

Change Healthcare [2]

Zebra

Zebra

Medica 2023 [2]

Medica 2023

WP [900×150]

WP [900x150]

Advertise with us

Advertise with us

Sectra SaaS

Sectra SaaS

Change Healthcare [2]

Change Healthcare [2]

Zebra

Zebra

Medica 2023 [2]

Medica 2023

Contact Us

Canadian Healthcare Technology
1118 Centre Street, Suite 207
Thornhill, Ontario, Canada L4J 7R9
Tel: 905-709-2330
Fax: 905-709-2258
info2@canhealth.com

  • Quick Links
    • Current Print Issue
    • Print Archive
    • Events
    • Vendors
    • About Us
  • Advertise
    • Publishing Schedule
    • Circulation
    • Unit Sizes and Rates
    • Mechanical Requirements
    • Electronic Advertising
    • White Papers
  • Subscribe
    • Print Edition
    • e-Messenger
    • White Papers
  • Resources
    • White Papers
    • Writers’ Guidelines
    • Privacy Policy
  • Topics
    • Administrative Solutions
    • Clinical Solutions
    • Companies
    • Continuing Care
    • Diagnostics
    • Education & Training
  •  
    • Electronic Records
    • Government & Policy
    • Infrastructure
    • Innovation
    • People
    • Privacy and Security

© 2023 Canadian Healthcare Technology

The content of Canadian Healthcare Technology is subject to copyright. Reproduction in whole or in part without prior written permission is strictly prohibited. Send all requests for permission to Jerry Zeidenberg, Publisher.

Search Site

Error: Enter a search term

  • Issues
    • Current Print Issue
    • Print Archive
  • Advertise
    • Publishing Schedule
    • Circulation
    • Unit Sizes and Rates
    • Mechanical Requirements
    • Electronic Advertising
    • White Papers
  • Subscribe
    • Print Edition
    • e-Messenger
    • White Papers
  • Events
  • Vendors
  • About Us